Cargando…

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer

BACKGROUND: The development of immune checkpoint inhibitors (ICIs) is a revolutionary milestone in the field of immune-oncology. However, the low response rate is the major problem of ICI treatment. The recent studies showed that response rate to single-agent programmed cell death protein 1 (PD-1)/p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Jiehan, Jin, Zheng, Zhang, Yiqun, Peng, Ling, Zhang, Yue, Zhu, Zhiruo, Wang, Yaohui, Tong, De, Yang, Yining, Wang, Jianfei, Yang, Yadong, Xiao, Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076602/ https://www.ncbi.nlm.nih.gov/pubmed/33927719 http://dx.doi.org/10.3389/fimmu.2021.646874

Ejemplares similares

Bioinformatics prediction of differential miRNAs in non-small cell lung cancer
por: Xiao, Kui, et al.
Publicado: (2021)

Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer
por: Xiao, Kui, et al.
Publicado: (2021)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection
por: Zheng, Meijun, et al.
Publicado: (2023)

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer
por: Gao, Xiang, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer
por: Looney, Timothy John, et al.
Publicado: (2020)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients
por: Zhang, Zhe, et al.
Publicado: (2023)

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
por: Engelsen, Agnete S. T., et al.
Publicado: (2022)

The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition
por: van Dorp, Jeroen, et al.
Publicado: (2023)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
por: Shu, Yang, et al.
Publicado: (2023)

Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer
por: Wang, Qinchuan, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
por: Frederico, Stephen C., et al.
Publicado: (2023)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients
por: Yang, Yong, et al.
Publicado: (2022)

Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Ling, Tao, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
por: Wang, Caie, et al.
Publicado: (2023)

Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia
por: Wang, Shuwen, et al.
Publicado: (2021)

Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
por: Eckert, Franziska, et al.
Publicado: (2019)

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
por: Anzar, Irantzu, et al.
Publicado: (2023)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
por: Yu, Lu, et al.
Publicado: (2022)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication
por: Dou, Shengjin, et al.
Publicado: (2021)

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition
por: Donlon, Noel E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kpcuv8e86n1kores3pvsl2si5h